

Prematurely ended statement

| | |
|----------------------------|---|
| EudraCT number | 2009-014844-13 |
| Full title of the study | Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation. |
| Protocol Code | 50-2009 |
| Sponsor | Charité – Universitätsmedizin Berlin |
| Sponsor representative | PD Dr. med. Christian Scholz, Med. Klinik u. Poliklinik II m.S. Onkologie und Hämatologie |
| Study contact | Vivantes Klinikum am Urban, Dieffenbachstr. 1, 10967 Berlin, christianw.scholz@vivantes.de |
| Product | Temsirolimus (Torisel/ Wyeth) |
| Date of early termination: | 2011/03/17 |
| Statement: | On behalf of the sponsor, this is confirm that no patient was recruited. |